Voronoi, Inc. (KOSDAQ:310210)

South Korea flag South Korea · Delayed Price · Currency is KRW
124,900
+8,900 (7.67%)
Jul 10, 2025, 3:30 PM KST
81.01%
Market Cap 2.09T
Revenue (ttm) n/a
Net Income (ttm) -40.15B
Shares Out 17.99M
EPS (ttm) -2,261.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 172,735
Average Volume 167,104
Open 118,200
Previous Close 116,000
Day's Range 117,500 - 126,200
52-Week Range 54,500 - 153,000
Beta 1.89
RSI 59.16
Earnings Date Aug 12, 2025

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 139
Stock Exchange KOSDAQ
Ticker Symbol 310210
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.